Last updated: February 23, 2026
What Is the Drug Associated with NDC 51407-0182?
NDC 51407-0182 corresponds to Vosevi (sofosbuvir/velpatasvir/voxilaprevir). It is approved by the FDA for the treatment of hepatitis C virus (HCV) infections, specifically for adults with:
- Chronic HCV genotypes 1, 2, 3, 4, 5, or 6
- Those who previously failed other direct-acting antivirals (DAAs)
- Patients with compensated cirrhosis
Vosevi is marketed by Gilead Sciences.
Market Landscape
Prevalence and Market Size
HCV affects approximately 2.4 million people in the U.S. and an estimated 58 million globally. The demand for treatment has increased with expanded screening and treatment guidelines.
Competitive Position
Vosevi competes with other pan-genotypic DAA regimens such as:
- Epclusa (sofosbuvir/velpatasvir, Gilead)
- Mavyret (glecaprevir/pibrentasvir, AbbVie)
- Zepatier (elbasvir/grazoprevir, Merck)
Vosevi primarily targets patients with prior treatment failure, a niche with limited current options.
Treatment Paradigm
Standard treatment durations are 12 weeks. Vosevi's efficacy in difficult-to-treat cases makes it attractive for specific patient subsets.
Pricing and Reimbursement Dynamics
Current List Price
As of 2023, the wholesale acquisition cost (WAC) for a 12-week course of Vosevi is approximately $74,760[1].
Pricing Comparison
| Drug |
List Price for 12-week Course |
Market Position |
| Vosevi |
$74,760 |
Indicated for treatment failure cases |
| Epclusa |
$74,760 |
Pan-genotypic, first-line therapy |
| Mavyret |
$26,400 |
Shorter duration, cost-effective for most genotypes |
| Zepatier |
$34,480 |
Genotype-specific, less expensive |
Vosevi’s higher price reflects its targeted use in patients who have failed other therapies rather than broad first-line therapy.
Reimbursement Trends
Private insurers and Medicare cover Vosevi with prior authorization, often requiring documentation of previous treatment failures. Medicaid coverage varies across states, with some negotiating supplemental rebates.
Price Trends and Future Outlook
Since launch in 2017, Vosevi’s price has remained steady. Competition and potential biosimilar or generic entrants remain unlikely in the near term due to Gilead’s patent protections and market exclusivity.
Gilead has previously maintained high prices for HCV drugs, sustaining margins despite broader market shifts towards negotiated discounts and value-based pricing models.
Market Dynamics and Growth Projections
Factors Impacting Sales
- HCV Screening Rates: Increased screening leads to higher diagnoses.
- Treatment Guidelines: Favor broader treatment access.
- Patient Population: Growing number of patients with prior treatment failure.
- Reimbursement Policies: Stricter prior authorization may limit broader use.
Revenue Projections
Analysts project that Vosevi's peak sales could reach $500 million annually in North America, assuming increased uptake among treatment-failure patients. Sales in Europe and Asia are expected to be lower due to pricing and access barriers.
Risks and Barriers
- Pricing Sensitivity: Payers press for discounts; high list prices could inhibit uptake.
- Market Competition: Greater use of pan-genotypic regimens reduces niche demand.
- Patent and Patent Litigation: Potential challenges could impact market exclusivity.
Summary: Price and Market Outlook
| Year |
Estimated Sales |
Pricing Assumption |
Notes |
| 2023 |
$350 million |
Steady list price, partial market penetration |
Market constrained by prior authorization and competition |
| 2024-2026 |
Up to $500 million |
Slight price reductions possible |
Growth driven by increased diagnosis and treatment failure cases |
Key Takeaways
- NDC 51407-0182 (Vosevi) has a high list price of approximately $74,760 for a 12-week course.
- The drug’s niche market comprises hep C patients with prior treatment failure.
- Total sales are projected to reach about $500 million annually by 2026, contingent on market acceptance.
- Market access challenges and competition influence price stability and sales growth.
- Price reductions or alternative therapies could impact future revenue estimates.
FAQs
1. What patient population does Vosevi primarily target?
Patients with chronic hepatitis C who have failed previous DAA therapies.
2. How does Vosevi compare in price to other DAA regimens?
It is comparable in list price to first-line pan-genotypic agents but priced higher for its specific niche.
3. Are there upcoming patent challenges that could affect Vosevi's market exclusivity?
No significant patent litigations are publicly anticipated within the next 2–3 years.
4. What factors could influence the future price of Vosevi?
Market competition, payer negotiations, regulatory changes, and introduction of generics.
5. What is the growth potential of Vosevi's market?
Limited to patients with prior treatment failure; overall growth depends on increased screening and diagnosis.
References
[1] Gilead Sciences. (2023). Vosevi pricing details. Retrieved from https://www.gilead.com/products/vosevi
